Australian Operations
   
Include All CSL Sites

ACARIZAX®

12 SQ-HDM oral lyophilisate. Sublingual tablet of standardised allergen extract from the house dust mite species Dermaophagoides pteronyssinus and Dermatophagoides farinae.

ACARIZAX® is allergy immunotherapy for the treatment of house dust mite allergic rhinitis and allergic asthma. This product is only available with a doctor’s prescription.

 

Who is this information for?
This information is relevant in Australia and is intended for people who have been prescribed this product or healthcare professionals.
 

Consumer Medicine Information
The Consumer Medicine Information (CMI) is a leaflet written for consumers. The CMI contains information about the medicine including:
  • What this product is used for
  • How it works
  • How this product is given
  • Side effects
PDF icon ACARIZAX Consumer Medicine Information (PDF, 136KB)


Product Information
Product Information contains information to ensure the safe and effective use of a medicine. This document is approved by the Therapeutic Goods Administration and made available by Seqirus for you if you are a:
  1. qualified healthcare professional; or
  2. consumer, provided you have read the Consumer Medicine Information for the product; want further information on the product; and agree to consult with your healthcare professional if you have any questions in relation to the Product Information.
PDF icon ACARIZAX Product Information (PDF, 153KB)

 




ACARIZAX® is a registered trademark of ALK-Abelló A/S, used under licence.

 

Last Updated: 11-08-2016
Share
LinkedIn Twitter Facebook Google+
© 2017 Seqirus